Tags

Type your tag names separated by a space and hit enter

Mantle cell lymphoma in the ocular adnexal region.
Ophthalmology 2005; 112(1):114-9O

Abstract

PURPOSE

To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region.

DESIGN

Retrospective review.

METHODS

The slides of 23 suspect patients were reevaluated with a panel of monoclonal antibodies, including anti-CD20, cyclin-D1, CD5, CD3, and p53 immunostains. Patients confirmed to have MCL were examined retrospectively on the basis of chart review.

RESULTS

Ten patients with periocular MCL were included in the study on the basis of characteristic histopathologic features and coexpression of nuclear cyclin-D1. This included 1 female and 9 male patients, with an age range of 32 to 84 years (median, 73.5 years). Median follow-up was 20 months (range, 5-172 months). Six of the 10 patients died, all of lymphoma. The orbit (90%) was most commonly involved followed by the lacrimal gland (50%) and lid (50%), with 90% of cases having lymphoma present at 2 or more periocular sites. Most had a primary periocular presentation (80%) that was associated with stage III/IV disease (80%), including atypical cells in the peripheral blood smear (60%) and bone marrow involvement (70%) at presentation. Three cases were CD5-negative, and 2 other cases showed composite histologic findings (MCL and follicular lymphoma and MCL and a plasma cell neoplasm). Fluorescent in situ hybridization performed in these 2 cases demonstrated t(11;14) in the MCL component. Actuarial survivals were median progression-free (PFS) survival, 12 months; median overall survival (OS), 57 months; 5-year PFS, 0; 5-year OS, 39%.

CONCLUSIONS

Mantle cell lymphoma presenting in the ocular adnexal region has a male predominance and tends to affect an elderly age group, as is typical of MCL involving nodal sites. A higher frequency of these tumors fail to co-express CD5, and composite lymphomas were observed in 20% of patients. Mantle cell lymphoma presenting in the ocular adnexal region is associated with advanced-stage disease and short PFS but an OS similar to MCL at other sites.

Authors+Show Affiliations

Department of Ophthalmology and Visual Sciences, Vancouver General Hospital and University of British Columbia, Vancouver, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15629830

Citation

Looi, Audrey, et al. "Mantle Cell Lymphoma in the Ocular Adnexal Region." Ophthalmology, vol. 112, no. 1, 2005, pp. 114-9.
Looi A, Gascoyne RD, Chhanabhai M, et al. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology. 2005;112(1):114-9.
Looi, A., Gascoyne, R. D., Chhanabhai, M., Connors, J. M., Rootman, J., & White, V. A. (2005). Mantle cell lymphoma in the ocular adnexal region. Ophthalmology, 112(1), pp. 114-9.
Looi A, et al. Mantle Cell Lymphoma in the Ocular Adnexal Region. Ophthalmology. 2005;112(1):114-9. PubMed PMID: 15629830.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mantle cell lymphoma in the ocular adnexal region. AU - Looi,Audrey, AU - Gascoyne,Randy D, AU - Chhanabhai,Mukesh, AU - Connors,Joseph M, AU - Rootman,Jack, AU - White,Valerie A, PY - 2004/06/24/received PY - 2004/07/23/accepted PY - 2005/1/5/pubmed PY - 2005/1/13/medline PY - 2005/1/5/entrez SP - 114 EP - 9 JF - Ophthalmology JO - Ophthalmology VL - 112 IS - 1 N2 - PURPOSE: To study the clinicopathologic features of mantle cell lymphoma (MCL) in the ocular adnexal region. DESIGN: Retrospective review. METHODS: The slides of 23 suspect patients were reevaluated with a panel of monoclonal antibodies, including anti-CD20, cyclin-D1, CD5, CD3, and p53 immunostains. Patients confirmed to have MCL were examined retrospectively on the basis of chart review. RESULTS: Ten patients with periocular MCL were included in the study on the basis of characteristic histopathologic features and coexpression of nuclear cyclin-D1. This included 1 female and 9 male patients, with an age range of 32 to 84 years (median, 73.5 years). Median follow-up was 20 months (range, 5-172 months). Six of the 10 patients died, all of lymphoma. The orbit (90%) was most commonly involved followed by the lacrimal gland (50%) and lid (50%), with 90% of cases having lymphoma present at 2 or more periocular sites. Most had a primary periocular presentation (80%) that was associated with stage III/IV disease (80%), including atypical cells in the peripheral blood smear (60%) and bone marrow involvement (70%) at presentation. Three cases were CD5-negative, and 2 other cases showed composite histologic findings (MCL and follicular lymphoma and MCL and a plasma cell neoplasm). Fluorescent in situ hybridization performed in these 2 cases demonstrated t(11;14) in the MCL component. Actuarial survivals were median progression-free (PFS) survival, 12 months; median overall survival (OS), 57 months; 5-year PFS, 0; 5-year OS, 39%. CONCLUSIONS: Mantle cell lymphoma presenting in the ocular adnexal region has a male predominance and tends to affect an elderly age group, as is typical of MCL involving nodal sites. A higher frequency of these tumors fail to co-express CD5, and composite lymphomas were observed in 20% of patients. Mantle cell lymphoma presenting in the ocular adnexal region is associated with advanced-stage disease and short PFS but an OS similar to MCL at other sites. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/15629830/Mantle_cell_lymphoma_in_the_ocular_adnexal_region_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(04)01268-0 DB - PRIME DP - Unbound Medicine ER -